Comparative binding of etretinate and acitretin to plasma proteins and erythrocytes.
The interactions of etretinate and its main metabolite acitretin with human plasma proteins have been investigated in vitro by an erythrocyte partitioning technique that allows a quantitative estimation of the plasma and erythrocyte binding. Etretinate was extensively lipoprotein-bound (75% of plasma etretinate), with a binding constant for its main low density lipoprotein carrier of 40 x 10(6) M-1, accounting for 48% of the total plasma-bound drug. Acitretin was mainly albumin-bound (91% of plasma acitretin), with a binding constant of 0.7 x 10(6) M-1. The total plasma binding of both drugs was > 99% and, in blood, the fractions associated with erythrocytes were 14.5 and 8.1% of the total amount for etretinate and acitretin, respectively.
Urien
S
S
Laboratoire de Pharmacologie, Faculté de Médecine, Université Paris XII, Créteil, France.
Claudepierre
P
P
Meyer
J
J
Brandt
R
R
Tillement
J P
JP
D017255:Acitretin / Q000097:blood*; D000328:Adult; D001798:Blood Proteins / Q000378:metabolism*; D003956:Dialysis / Q000379:methods; D004910:Erythrocyte Membrane / Q000378:metabolism; D004912:Erythrocytes / Q000378:metabolism*; D005050:Etretinate / Q000097:blood*; D006801:Humans; D007700:Kinetics; D008074:Lipoproteins / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D011485:Protein Binding
D001798:Blood Proteins; D008074:Lipoproteins; D008077:Lipoproteins, LDL; D005050:Etretinate; D017255:Acitretin